UA105760C2 - Антитіло проти bst2 - Google Patents

Антитіло проти bst2

Info

Publication number
UA105760C2
UA105760C2 UAA201005531A UAA201005531A UA105760C2 UA 105760 C2 UA105760 C2 UA 105760C2 UA A201005531 A UAA201005531 A UA A201005531A UA A201005531 A UAA201005531 A UA A201005531A UA 105760 C2 UA105760 C2 UA 105760C2
Authority
UA
Ukraine
Prior art keywords
antibody
bst2d
bst2
tissue
specifically
Prior art date
Application number
UAA201005531A
Other languages
English (en)
Russian (ru)
Inventor
Юміко Камоґава
Сахорі Намікі
Мінквон То
Кодзі Ісида
Original Assignee
Ес-Бі-Ай Біотех Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ес-Бі-Ай Біотех Ко., Лтд. filed Critical Ес-Бі-Ай Біотех Ко., Лтд.
Publication of UA105760C2 publication Critical patent/UA105760C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Винахід належить до антитіла проти BST2 людини, яке зв'язується з антигеном BST2D людини, що експресується з високими рівнями у ракових клітинах, але по суті не зв'язується з антигеном BST2H людини. Також запропоновано терапевтичні та діагностичні засоби, які включають антитіло цього винаходу, які специфічно виявляють тканини, що експресують BST2D.
UAA201005531A 2007-10-16 2008-10-16 Антитіло проти bst2 UA105760C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007269470 2007-10-16
PCT/JP2008/068794 WO2009051201A1 (ja) 2007-10-16 2008-10-16 抗bst2抗体

Publications (1)

Publication Number Publication Date
UA105760C2 true UA105760C2 (uk) 2014-06-25

Family

ID=40567462

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201005531A UA105760C2 (uk) 2007-10-16 2008-10-16 Антитіло проти bst2

Country Status (15)

Country Link
US (2) US8529896B2 (uk)
EP (1) EP2210939A4 (uk)
JP (1) JP5558825B2 (uk)
KR (1) KR20100090258A (uk)
CN (2) CN101952426B (uk)
AU (1) AU2008312858A1 (uk)
BR (1) BRPI0817427A8 (uk)
CA (1) CA2702939A1 (uk)
HK (1) HK1153502A1 (uk)
IL (1) IL205073A (uk)
MX (1) MX2010004251A (uk)
NZ (1) NZ585394A (uk)
RU (1) RU2010119450A (uk)
UA (1) UA105760C2 (uk)
WO (1) WO2009051201A1 (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
WO2014066271A1 (en) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
JP6448614B2 (ja) * 2013-03-15 2019-01-09 ベス イスラエル デアコネス メディカル センター インコーポレイテッド コンフォメーション特異的抗体の発生および使用のための方法および組成物
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
CN110964108B (zh) 2014-08-05 2023-07-07 中美冠科生物技术（太仓）有限公司 抗pd-l1抗体
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
EP4168029A1 (en) * 2020-06-19 2023-04-26 Board of Regents, The University of Texas System Anti-bst2 antibodies targeting bst2 long isoform

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305121A (en) * 1884-09-16 Razor-strop
TW474991B (en) * 1993-10-15 2002-02-01 Toshio Hirano Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof
WO1998035698A1 (fr) 1997-02-12 1998-08-20 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs lymphocitaires
ES2255247T3 (es) 1998-02-25 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Gen genomico que codifica la proteina antigenica hm1.24 y su promotor.
ATE457318T1 (de) * 2000-12-28 2010-02-15 Kyowa Hakko Kirin Co Ltd Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
JP4297689B2 (ja) * 2001-04-13 2009-07-15 中外製薬株式会社 抗原の発現量を定量する方法
US8603481B2 (en) 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
CA2570602A1 (en) 2004-06-11 2006-01-26 Ginkgo Biomedical Research Institute Co., Ltd. Agents for regulating the activity of interferon-producing cells
JPWO2006013923A1 (ja) * 2004-08-05 2008-05-01 Ｓｂｉバイオテック株式会社 自己免疫疾患を伴う関節炎の治療剤
WO2006054748A1 (ja) * 2004-11-22 2006-05-26 Ginkgo Biomedical Research Institute Co., Ltd. 腎炎の治療剤
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation

Also Published As

Publication number Publication date
NZ585394A (en) 2012-05-25
EP2210939A1 (en) 2010-07-28
WO2009051201A1 (ja) 2009-04-23
KR20100090258A (ko) 2010-08-13
US20130336967A1 (en) 2013-12-19
HK1153502A1 (en) 2012-03-30
BRPI0817427A2 (pt) 2015-06-16
EP2210939A4 (en) 2012-08-08
IL205073A (en) 2014-07-31
US20100278832A1 (en) 2010-11-04
IL205073A0 (en) 2010-11-30
AU2008312858A1 (en) 2009-04-23
RU2010119450A (ru) 2011-11-27
CA2702939A1 (en) 2009-04-23
JP5558825B2 (ja) 2014-07-23
JPWO2009051201A1 (ja) 2011-03-03
MX2010004251A (es) 2010-08-30
CN101952426A (zh) 2011-01-19
BRPI0817427A8 (pt) 2019-01-29
CN104031150A (zh) 2014-09-10
US8529896B2 (en) 2013-09-10
CN101952426B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
MX2010004251A (es) Anticuerpo anti-bst2.
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
WO2010096434A3 (en) Specific binding proteins and uses thereof
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BR112013004266A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos.
CR20120506A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
IN2014CN03936A (uk)
CA2749846A1 (en) Methods of determining patient response by measurement of her-3
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201071068A1 (ru) Антитела к tyrp1
TR201902972T4 (tr) Kanseri tespit etmek için yöntem.
WO2010031749A9 (en) Compositions and methods for detecting tlr3
RU2014102595A (ru) Способ введения и лечения
RU2016102202A (ru) Биологический маркер опухоли
WO2006083957A3 (en) Tat-001 and methods of assessing and treating cancer
WO2012077983A3 (ko) Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트
WO2007005559A3 (en) Tat-005 and methods of assessing and treating cancer
WO2006133145A3 (en) Tat-007 and methods of assessing and treating cancer
WO2006116681A3 (en) Tat-003 and methods of assessing and treating cancer
WO2007089793A3 (en) Tat-041 and methods of assessing and treating cancer